Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Investing Activities (2021 - 2025)

Kezar Life Sciences' Cash from Investing Activities history spans 5 years, with the latest figure at $15.7 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 34.7% year-over-year to $15.7 million; the TTM value through Sep 2025 reached $64.6 million, down 23.61%, while the annual FY2024 figure was $80.4 million, 5.76% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was $15.7 million at Kezar Life Sciences, up from $11.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $38.5 million in Q3 2021 and bottomed at -$82.5 million in Q4 2021.
  • The 5-year median for Cash from Investing Activities is $13.7 million (2025), against an average of $4.1 million.
  • The largest annual shift saw Cash from Investing Activities tumbled 8565.65% in 2022 before it soared 774.37% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$82.5 million in 2021, then skyrocketed by 89.5% to -$8.7 million in 2022, then skyrocketed by 421.88% to $27.9 million in 2023, then decreased by 14.83% to $23.7 million in 2024, then crashed by 33.83% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Cash from Investing Activities are $15.7 million (Q3 2025), $11.4 million (Q2 2025), and $13.7 million (Q1 2025).